LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.35 6.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

4.35

Belangrijke statistieken
By Trading Economics
Inkomsten	27M 2.5M
Verkoop	9M 11M
Winstmarge	23.494
Werknemers	44
EBITDA	27M 2.6M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	72M 711M
Vorige openingsprijs	-2.01
Vorige sluitingsprijs	4.35

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2025, 23:59 UTC

Acquisities, Fusies, Overnames

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sep 2025, 22:02 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sep 2025, 17:01 UTC

Belangrijke Marktbewegers

Tron Shares Rise After New Investment From Bravemorning

8 sep 2025, 16:14 UTC

Belangrijke Marktbewegers

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sep 2025, 16:13 UTC

Belangrijke Marktbewegers

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sep 2025, 23:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 sep 2025, 23:12 UTC

Marktinformatie

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sep 2025, 22:56 UTC

Marktinformatie

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sep 2025, 22:23 UTC

Marktinformatie

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sep 2025, 21:51 UTC

Marktinformatie

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sep 2025, 21:47 UTC

Belangrijke Marktbewegers

Microsoft Signs $17.4B AI Deal With Nebius

8 sep 2025, 21:33 UTC

Acquisities, Fusies, Overnames

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sep 2025, 21:20 UTC

Acquisities, Fusies, Overnames

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sep 2025, 21:19 UTC

Acquisities, Fusies, Overnames

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sep 2025, 21:18 UTC

Acquisities, Fusies, Overnames

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sep 2025, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 19:33 UTC

Marktinformatie

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sep 2025, 19:22 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sep 2025, 19:02 UTC

Marktinformatie

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 sep 2025, 18:24 UTC

Marktinformatie

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sep 2025, 17:29 UTC

Marktinformatie

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sep 2025, 16:59 UTC

Marktinformatie

Acquisities, Fusies, Overnames

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sep 2025, 16:36 UTC

Marktinformatie

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sep 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 sep 2025, 16:16 UTC

Winsten

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 sep 2025, 16:04 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.